This bill restructures how Medicare pays for new drugs, biologics, devices, and services used in end‑stage renal disease (ESRD) care. It extends transitional payment pathways and requires HHS to establish a permanent add‑on mechanism after the transitional period, modifies eligibility and claim rules, and forces Medicare Advantage plans to accommodate those transitional payments.
Beyond payment mechanics, the bill also creates a labor‑sensitivity adjustment to the ESRD market basket, adds chronic kidney disease screening to the Medicare Annual Wellness Visit, and expands the Medicare kidney disease education benefit to more patients, providers, and renal dialysis facilities. The statute sets multiple implementation rules and effective dates designed to start on January 1, 2026.
At a Glance
What It Does
Directs HHS to extend transitional add‑on payments for new renal dialysis drugs and devices, create a permanent post‑transition add‑on for drugs/biologics, include certain capital assets in device transitional payments, and require direct payments for these transitional items when beneficiaries are enrolled in Medicare Advantage. It also adds a forecast error adjustment to ESRD market basket updates and expands Medicare prevention and education benefits for kidney disease.
Who It Affects
Dialysis providers and renal dialysis facilities, drug and device manufacturers that pursue renal indications, CMS (payment administrators), Medicare Advantage plans, and Medicare beneficiaries with or at risk of chronic kidney disease.
Why It Matters
The bill changes incentive and revenue flows for ESRD care: manufacturers gain longer and more predictable reimbursement windows; providers and facilities get new add‑on payments and separate education payments; CMS and Medicare Advantage must operationalize cross‑program payment flows. That affects adoption of novel therapies and near‑term Medicare spending.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill updates Title XVIII to lower adoption barriers for new ESRD therapies by lengthening and then converting temporary transitional payments into a durable reimbursement add‑on. For drugs and biologics used during dialysis, HHS must pay a transitional drug add‑on payment for at least three years for eligible products and then establish a permanent post‑transition add‑on tied to observed utilization and sales data.
The statute prescribes how to calculate that add‑on (see below), requires annual inflation updates, and prohibits that add‑on from being shifted through budget neutrality or certain case‑mix adjustments.
For devices and supplies the bill extends the transitional add‑on period to at least three years, makes devices with FDA expedited (515B) designation eligible for transitional support beginning in 2026, and explicitly allows capital‑related assets that meet the device criteria to receive transitional and post‑transition add‑ons. The statute also amends the statutory definition of “renal dialysis services” to tighten which drugs count as dialysis‑related and requires an AY claim modifier to flag drugs and biologics that meet the new standard.The bill directs CMS to make direct payments to providers and dialysis facilities for items receiving transitional add‑ons even when beneficiaries are enrolled in Medicare Advantage, tying the amount to the ESRD prospective payment system’s add‑on and requiring payments for the transitional duration.
Separately, it requires CMS to compute a forecast error adjustment to the ESRD market basket labor update beginning in 2026—initially capturing cumulative forecast error for 2021‑2022 and thereafter comparing the most recently available forecast and actual price changes to trigger adjustments.On prevention and education, the bill authorizes the Secretary to define and include chronic kidney disease screening within the Medicare Annual Wellness Visit and expands the kidney disease education benefit to cover stage V disease and services provided by physician assistants, nurse practitioners, clinical nurse specialists, and qualified personnel in renal dialysis facilities. It also carves kidney disease education out of the ESRD bundled payment so facilities can bill those services separately on an assignment‑related basis under the physician fee schedule.
The Five Things You Need to Know
The bill requires a minimum 3‑year transitional drug add‑on payment (TDAPA) period for new renal dialysis drugs/biologics furnished on or after January 1, 2026.
It establishes a permanent post‑TDAPA add‑on calculated as 65% of total expenditures for the product divided by the number of dialysis services during which it was administered, with annual inflation updates.
If Average Sales Price data are zero or negative, the statute directs use of 100% of Wholesale Acquisition Cost as a fallback, and if WAC is unavailable CMS must use the manufacturer’s invoice.
Beginning January 1, 2026, devices with FDA 515B expedited designation become eligible for the device transitional add‑on, and capital‑related assets may receive transitional and post‑transition add‑ons.
The market basket update receives a forecast‑error adjustment starting in 2026: the initial adjustment incorporates cumulative forecast error for 2021–2022 and future adjustments trigger when forecast vs actual price change differs by more than 0.5 percentage points.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Minimum 3‑Year TDAPA Period for New Renal Drugs/Biologics
This provision mandates that HHS pay the transitional drug add‑on payment for any qualifying new renal dialysis drug or biologic for at least three years when the product meets the statutory criteria and is furnished on or after January 1, 2026. Practically, manufacturers and providers gain a longer predictable transitional window to support early adoption and real‑world use while CMS collects utilization and price data.
Permanent Post‑TDAPA Add‑On: Formula and Limits
The bill creates a statutory post‑TDAPA add‑on for drugs that received TDAPA and were furnished beginning in 2024, effective for claims on or after January 1, 2026. CMS must compute expenditures for the drug over a recent reference period, divide by the total number of dialysis services where the drug was administered, and set the permanent add‑on equal to 65% of that per‑service amount. The add‑on must be updated annually for inflation and applied without budget neutrality or certain case‑mix offsets—an explicit policy choice to increase net payments for these products.
Narrowing 'Renal Dialysis Services' and Claim‑Level Flags
The bill tightens the statutory definition of renal dialysis services so that certain drugs used to treat comorbid conditions are excluded if they meet the post‑2025 approval and non‑substitution criteria. To operationalize this, CMS must require an AY modifier (or successor) on claims for drugs or biologics that fall under the exclusion language—creating a new coding and compliance task for providers and billing systems.
Device Transitional Payments: 515B Eligibility and Capital Assets
This section extends the device transitional add‑on to at least three years for qualifying renal dialysis devices furnished on or after January 1, 2026, makes FDA 515B expedited devices explicitly eligible, and removes the regulatory exclusion of capital‑related assets so qualifying capital devices can receive transitional and post‑transition add‑ons. Facilities that invest in new capital equipment should expect new revenue pathways, and CMS must update its eligibility and valuation processes accordingly.
Medicare Advantage: Direct Payments for Transitional Items
The statute amends the MA payment rules to require the Secretary to make direct payment adjustments to providers or dialysis facilities for enrollees receiving items that have TDAPA or device transitional add‑ons. The amount equals the ESRD prospective payment system’s add‑on, and payments run for the duration of the transitional period. That forces a cross‑program payment flow—MA plans remain responsible for enrollee benefits but CMS will route specific transitional payments directly to providers.
Forecast Error Adjustment to ESRD Market Basket Updates
Starting in 2026 CMS must compute an adjustment to the annual ESRD payment update factor to correct forecast errors in the market basket. The initial adjustment incorporates cumulative forecast error for 2021–2022; thereafter CMS uses the most recently available final data. The statute triggers the adjustment when the forecast versus actual price change differs by more than 0.5 percentage points, adding a formal mechanism to dampen persistent mis‑forecasting of input prices such as labor.
Add CKD Screening to the Annual Wellness Visit
The bill authorizes the Secretary to define chronic kidney disease screening and include it in the Medicare Annual Wellness Visit (AWV). Inclusion in the AWV makes screening part of established preventive care and gives providers an explicit benefit vehicle to identify patients at risk earlier in the course of disease.
Expand Kidney Disease Education and Separate Facility Payment
This provision broadens the kidney disease education (KDE) benefit to stage V patients and authorizes PAs, NPs, and clinical nurse specialists assisting in kidney care to furnish KDE. Crucially, it permits renal dialysis facilities that deliver KDE to bill separately—payments are excluded from the ESRD bundle and are paid on an assignment‑related basis under the physician fee schedule, creating a new revenue stream for facilities that provide education services.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with ESRD and those at high risk: Earlier and broader coverage for CKD screening, expanded education for stage V patients, and easier access to new dialysis‑related drugs, biologics, and devices should increase therapeutic options and informed decision‑making.
- Dialysis providers and renal dialysis facilities: Transitional payments, a statutory post‑TDAPA add‑on, inclusion of capital assets for device add‑ons, and the separate billing pathway for kidney disease education create new and clearer reimbursement streams.
- Drug and device manufacturers targeting renal indications: A guaranteed minimum transitional period and a statutory formula for post‑transition reimbursement improve revenue predictability and lower commercial risk for launching renal products.
- Medicare Advantage enrollees and their treating providers: The direct payment mechanism ensures providers receive transitional add‑on dollars even when beneficiaries are MA enrollees, reducing barriers to offering novel therapies within MA networks.
Who Bears the Cost
- Medicare trust funds and taxpayers: The bill explicitly removes budget neutrality for the post‑TDAPA add‑on and expands payments across multiple fronts, increasing federal outlays for ESRD care.
- CMS and its contractors: Implementing new payment formulas, fallbacks for pricing data, AY modifier coding, MA direct payments, and market basket forecast adjustments will require systems, guidance, audit rules, and staff time.
- Medicare Advantage plans: Although MA plans remain responsible for enrollee benefits, the law directs CMS to make direct payments for transitional items—creating administrative coordination questions and potential downstream consequences for plan design and provider contracting.
- Smaller dialysis operators with limited billing capacity: New claim modifiers, separate physician fee schedule billing for education, and tracking utilization for add‑on calculations increase compliance and billing complexity that may disproportionately affect smaller facilities.
Key Issues
The Core Tension
The central dilemma is a trade‑off between accelerating patient access to high‑cost, potentially beneficial kidney therapies and protecting Medicare’s fiscal sustainability and incentive structure: the bill deliberately raises payments and reduces budget neutrality to reward innovation and remove adoption barriers, but those same provisions risk higher program spending, distorted investment incentives (especially for capital purchases), and practical implementation challenges that could produce billing complexity and audit exposure.
The bill prioritizes access to innovation by lengthening transitional windows and creating a statutory post‑TDAPA add‑on that is explicitly non‑budget‑neutral. That raises immediate fiscal exposure: higher net Medicare payments for selected drugs, biologics, and devices can accelerate adoption but also increase program spending without an offset.
The statute prescribes a somewhat granular pricing hierarchy (ASP, fallback to WAC, fallback to manufacturer invoice) to populate the post‑transition calculation, but the quality and timeliness of those data will directly affect add‑on accuracy and could produce volatile or disputable pricing inputs in early years.
Operationally, multiple new requirements create implementation risk. The AY modifier and the carve‑out for comorbidity drugs require precise coding guidance and provider education; misclassification could produce payment errors or audits.
Including capital assets in device transitional payments changes investment incentives and may encourage acquisition of high‑cost equipment that benefits from add‑ons, shifting capital allocation decisions. The MA direct payment mechanism reduces a key barrier to offering innovative therapies under MA, but it also complicates MA plan/provider economics and raises questions about reconciliation, encounter data, and risk adjustment treatments.
Finally, the forecast error adjustment for labor indexes is a technical fix that depends on robust final price indices; setting the 0.5 percentage point trigger is a blunt instrument that may under‑ or over‑correct in different market conditions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.